Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Shares Shorted: Short Interest Up 104.5% in September

Enlivex Therapeutics Ltd. (NASDAQ:ENLV) was the recipient of a large increase in short interest during the month of September. As of September 30th, there was short interest totaling 98,600 shares, an increase of 104.5% from the September 15th total of 48,204 shares. Currently, 0.6% of the shares of the company are short sold. Based on an average daily trading volume, of 611,232 shares, the short-interest ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on ENLV shares. Weiss Ratings reiterated a “sell (d)” rating on shares of Enlivex Therapeutics in a research report on Tuesday, September 22nd. Wall Street Zen raised Enlivex Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Finally, Zacks Research cut Enlivex Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, October 2nd. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $247.50.

Enlivex Therapeutics Stock Performance

NASDAQ:ENLV opened at $0.22 on Wednesday. Enlivex Therapeutics has a one year low of $0.22 and a one year high of $27.15. The business has a fifty day moving average price of $1.07 and a 200-day moving average price of $6.81.

Institutional Trading of Enlivex Therapeutics

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE increased its position in Enlivex Therapeutics by 53.2% in the first quarter. Bank of America Corp DE now owns 130,401 shares of the company’s stock worth $121,000 after buying an additional 45,303 shares in the last quarter. Susquehanna International Group LLP raised its stake in shares of Enlivex Therapeutics by 1,428.5% in the second quarter. Susquehanna International Group LLP now owns 157,648 shares of the company’s stock worth $87,000 after buying an additional 147,334 shares during the period. Finally, WINTON GROUP Ltd purchased a new position in shares of Enlivex Therapeutics during the 2nd quarter valued at about $55,000. Institutional investors own 1.02% of the company’s stock.

Enlivex Therapeutics Company Profile

Enlivex Therapeutics Ltd. is a clinical-stage biotechnology company developing immunotherapies designed to restore immune-system balance in conditions associated with excessive or dysregulated inflammation. The company is based in Israel and trades on the Nasdaq under the symbol ENLV.

Enlivex’s lead product candidate is Allocetra, an investigational, off-the-shelf cell therapy intended to reprogram immune cells known as macrophages and promote immune homeostasis. The therapy is being studied as a potential treatment for severe inflammatory conditions, including sepsis and osteoarthritis of the knee.

The company’s clinical development activities have included studies in Israel and other locations, with programs focused on evaluating Allocetra’s safety and potential efficacy.